PALATINE, Ill., Sept. 2, 2008 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NasdaqCM:ACUR - News) announced today that Andy Reddick has resumed full responsibilities as President and Chief Executive Officer following a medical leave of absence initiated in February of this year. The Company expects Mr. Reddick’s travel schedule will be limited for the foreseeable future.
About Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) (abuse deterrent) Technology and related product candidates. For more information, please visit http://www.acurapharm.com.
The Acura Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4847
Contact:
Acura Pharmaceuticals, Inc. Peter A. Clemens, SVP Investor Relations & CFO 847-705-7709
Source: Acura Pharmaceuticals, Inc.
